J. Fra - Concepedia

Author

J. Fra

Hospital Universitario Central de Asturias ORCID

Also Known As

J Fra, J Rodríguez, J. Fra, J. Fra Rodríguez, Joaquin Fra, Joaquín Fra, Joaquín Fra Rodríguez, Joaquín Rodriguez Fra

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

Hospital Universitario Central de Asturias Hospital de Sant Pau Hospital Clínic de Barcelona Hospital Clínico Universitario Lozano Blesa Hospital Universitario Miguel Servet

About

J. Fra is an author at Hospital Universitario Central de Asturias specializing in oncology, medicine, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	209
2	Pharmacology	4	4	110
3	Health Sciences	2	2	42
4	Gastroenterology	1	1	57
5	Pathology	1	1	13

J. Fra

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III Study Marie‐Françoise Avril, Steinar Aamdal, Jean‐Jacques Grob, Journal of Clinical Oncology	2004	470
Randomized Phase II Study Comparing Gemcitabine Plus Dacarbazine Versus Dacarbazine Alone in Patients With Previously Treated Soft Tissue Sarcoma: A Spanish Group for Research on Sarcomas Study Xavier García del Muro, Antonio López–Pousa, Joan Maurel, Journal of Clinical Oncology	2011	293
Efficacy of Sequential High-Dose Doxorubicin and Ifosfamide Compared With Standard-Dose Doxorubicin in Patients With Advanced Soft Tissue Sarcoma: An Open-Label Randomized Phase II Study of the Spanish Group for Research on Sarcomas Joan Maurel, Antonio López–Pousa, R. de las Peñas, Journal of Clinical Oncology	2009	73
Role of Surgery in Patients with Recurrent, Metastatic, or Unresectable Locally Advanced Gastrointestinal Stromal Tumors Sensitive to Imatinib: A Retrospective Analysis of the Spanish Group for Research on Sarcoma (GEIS) Jordi Rubió‐Casadevall, Javier Martínez‐Trufero, Xabier García‐Albéniz, Annals of Surgical Oncology Spanish GroupSurgical OncologyGastrointestinal OncologyMedicineGastroenterology	2015	57
Prospective randomised phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy Emilio Esteban, Luis González de Sande, Yolanda Fernández, Annals of Oncology OncologyDocetaxel Versus PaclitaxelCancer ManagementPharmacologyClinical Trials	2003	54
Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas Raquel Losa, J. Fra, Antonio López–Pousa, Cancer Chemotherapy and Pharmacology MedicineSurgical PathologyPhase Ii StudyOncologyRadiation Oncology	2006	27
Pulmonary toxicity in patients treated with gemcitabine plus vinorelbine or docetaxel for advanced non-small cell lung cancer: outcome data on a randomized phase II study Emilio Esteban, N. Villanueva, I. Muñiz, Investigational New Drugs OncologyMedicinePulmonary PharmacologyPulmonary MedicinePharmacotherapy	2007	24
Sequential dose‐dense doxorubicin and ifosfamide for advanced soft tissue sarcomas Joan Maurel, J. Fra, Antonio López–Pousa, Cancer	2004	21
Phase I clinical trial of fixed–dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma, with assessment of gemcitabine triphosphate accumulation J. Buesa, Raquel Losa, Aida Fernández, Cancer	2004	21
Long-term biomonitoring of breast cancer patients under adjuvant chemotherapy: the comet assay as a possible predictive factor E. Uriol, Marta Sierra, Miguel A. Comendador, Mutagenesis	2012	19

Page 1